Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia

Haematologica. 2004 May;89(5):615-7.

Abstract

Eleven patients with advanced APL were treated with ATO (0.15 mg/Kg daily). Eight (73%) achieved molecular CR, but 5 relapsed, 1 died in molecular CR, 1 was lost to follow-up and 1 is still alive in CR after allogeneic transplantation. We suggest that ATO may be effective also in advanced APL, but given the short CR, it seems indicated only in patients eligible for transplant procedures.

Publication types

  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Arsenic Trioxide
  • Arsenicals / therapeutic use*
  • Bone Marrow Transplantation
  • Child, Preschool
  • Combined Modality Therapy
  • Female
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Male
  • Middle Aged
  • Oxides / therapeutic use*
  • Recurrence
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Arsenicals
  • Oxides
  • Arsenic Trioxide